fda warning bpc-157 not approved 2024 2025 to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters Regulatory Alert: The Legal Status

At-a-Glance: B12 vs

It works by measuring the percentage of haemoglobin molecules in red blood cells that have become bound to glucose over the preceding two to three months

Besides counteraction of bleeding aspirin-gastric ulcers (14), BPC 157 also counteracts other NSAIDs-toxicity, using the same dose range (8-14), namely, gastric and small intestine ulcers (i.e., induced by indomethacin, diclofenac, ibuprofen, celecoxib (8-14)), hepatotoxicity (paracetamol, diclofenac, ibuprofen, celecoxib) (8-14) and encephalopathy (paracetamol, diclofenac, ibuprofen, celecoxib) (8-14)

The sponsor notifies the TGA of the trial rather than waiting for the TGA to evaluate it (TGA, 2026a)

The most probable scenario is that compounding pharmacies would be permitted to produce certain peptides under FDA oversight, allowing licensed health-care professionals to prescribe them. This would be similar to what happened with semaglutide, the active ingredient in GLP-1 medications like Ozempic, he says